Lb Pharmaceuticals (LBRX) Accounts Payables (2024 - 2026)

Lb Pharmaceuticals' Accounts Payables history runs 3 years deep, the most recent figure standing at $7.1 million for Q1 2026.

• In Q1 2026, Accounts Payables changed N/A year-over-year to $7.1 million; the TTM figure through Mar 2026 stood at $7.1 million (changed N/A YoY), while the FY2025 annual figure was $2.1 million, down 8.32% from the prior year.
• Accounts Payables was $7.1 million for Q1 2026 at Lb Pharmaceuticals, up from $2.1 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $7.1 million in Q1 2026 to a low of $2.1 million in Q4 2025.
• Historically, Accounts Payables has averaged $3.5 million across 3 years, with a median of $2.5 million in 2024.
• Biggest YoY gain for Accounts Payables was 8.32% in 2025; the steepest drop was 8.32% in 2025.
• A 3-year view of Accounts Payables shows it stood at $2.3 million in 2024, then fell by 8.32% to $2.1 million in 2025, then surged by 234.7% to $7.1 million in 2026.
• The last three Accounts Payables figures came in at $7.1 million (Q1 2026), $2.1 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.